Cost-effectiveness of lapatinib plus letrozole in her2-positive, hormone receptor–positive metastatic breast cancer in Canada

T.E. Delea; J. Amdahl; A. Chit; M.M. Amonkar

doi:10.3747/co.20.1394

Cost-effectiveness of lapatinib plus letrozole in her2-positive, hormone receptor–positive metastatic breast cancer in Canada

Current Oncology ◽

10.3747/co.20.1394 ◽

2013 ◽

Vol 20 (5) ◽

pp. 371 ◽

Cited By ~ 13

Author(s):

T.E. Delea ◽

J. Amdahl ◽

A. Chit ◽

M.M. Amonkar

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cost Effectiveness ◽

Hormone Receptor ◽

Metastatic Breast ◽

Her2 Positive ◽

Hormone Receptor Positive

Download Full-text

Erratum to: Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-014-3107-3 ◽

2014 ◽

Vol 147 (2) ◽

pp. 443-443 ◽

Cited By ~ 1

Author(s):

Vakaramoko Diaby ◽

Georges Adunlin ◽

Simon B. Zeichner ◽

Kiran Avancha ◽

Gilberto Lopes ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cost Effectiveness ◽

Hormone Receptor ◽

Metastatic Breast ◽

Cost Effectiveness Analysis ◽

Hormone Receptor Positive ◽

Effectiveness Analysis

Download Full-text

Letrozole in Combination with Trastuzumab Is Superior to Letrozole Monotherapy as First Line Treatment in Patients with Hormone-Receptor-Positive, HER2- Positive Metastatic Breast Cancer (MBC) – Results of theeLEcTRATrial.

10.1158/0008-5472.sabcs-09-4094 ◽

2009 ◽

Cited By ~ 6

Author(s):

J. Huober ◽

P. Fasching ◽

S. Paepke ◽

E. Kubista ◽

M. Barsoum ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Hormone Receptor Positive ◽

First Line Treatment

Download Full-text

Abstract OT1-03-06: Phase IB/II clinical trial to evaluate safety and efficacy of tucatinib in combination with palbociclib and letrozole in patients with hormone receptor positive and HER2-positive metastatic breast cancer

10.1158/1538-7445.sabcs17-ot1-03-06 ◽

2018 ◽

Cited By ~ 1

Author(s):

E Shagisultanova ◽

J Diamond ◽

A Stopeck ◽

L Pusztai ◽

R O'Regan ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Metastatic Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Her2 Positive ◽

Safety And Efficacy ◽

Phase Ib ◽

Hormone Receptor Positive

Download Full-text

Abstract OT1-02-04: The DETECT V-study – Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo- or endocrine therapy in patients with HER2-positive and hormone-receptor positive metastatic breast cancer

10.1158/1538-7445.sabcs16-ot1-02-04 ◽

2017 ◽

Cited By ~ 1

Author(s):

A Polasik ◽

A Schramm ◽

TWP Friedl ◽

B Rack ◽

E Trapp ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Targeted Therapy ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Metastatic Breast ◽

Her2 Positive ◽

Hormone Receptor Positive

Download Full-text

Abstract P5-20-19: PAM50 intrinsic subtype predicts survival outcome in HER2-positive/hormone receptor-positive metastatic breast cancer treated with palbociclib and trastuzumab: a correlative analysis of the PATRICIA (SOLTI 13-03) trial

10.1158/1538-7445.sabcs17-p5-20-19 ◽

2018 ◽

Cited By ~ 4

Author(s):

E Ciruelos ◽

P Villagrasa ◽

L Paré ◽

M Oliveira ◽

L de la Peña ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Intrinsic Subtype ◽

Survival Outcome ◽

Her2 Positive ◽

Correlative Analysis ◽

Hormone Receptor Positive

Download Full-text

First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis

Breast Cancer ◽

10.1007/s12282-019-01034-6 ◽

2019 ◽

Vol 27 (3) ◽

pp. 399-404 ◽

Cited By ~ 1

Author(s):

Weiting Liao ◽

Jiaxing Huang ◽

Qiuji Wu ◽

Feng Wen ◽

Nan Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cost Effectiveness ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Metastatic Breast ◽

Cost Effectiveness Analysis ◽

First Line ◽

Hormone Receptor Positive ◽

Effectiveness Analysis

Download Full-text

ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): A retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials

Annals of Oncology ◽

10.1093/annonc/mdz239.030 ◽

2019 ◽

Vol 30 ◽

pp. v36-v37

Author(s):

N. Chic ◽

T. Pascual ◽

F. Brasó-Maristany ◽

P. Villagrasa Gonzalez ◽

L. Pare Brunet ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Retrospective Analysis ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Metastatic Breast ◽

Her2 Positive ◽

Hormone Receptor Positive ◽

Erbb2 Mrna

Download Full-text

Long-term remission of hormone receptor-positive/HER2-positive metastatic breast cancer due to combined treatment with everolimus/trastuzumab/exemestane: A case report

Oncology Letters ◽

10.3892/ol.2017.6311 ◽

2017 ◽

Vol 14 (2) ◽

pp. 1725-1730 ◽

Cited By ~ 2

Author(s):

Jian Wang ◽

Chunxiao Sun ◽

Xiang Huang ◽

Jinrong Qiu ◽

Yongmei Yin

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Case Report ◽

Hormone Receptor ◽

Combined Treatment ◽

Metastatic Breast ◽

Her2 Positive ◽

Hormone Receptor Positive

Download Full-text

First‐Line Treatment Patterns and Clinical Outcomes in Patients With HER2‐Positive and Hormone Receptor‐Positive Metastatic Breast Cancer From registHER

The Oncologist ◽

10.1634/theoncologist.2012-0414 ◽

2013 ◽

Vol 18 (5) ◽

pp. 501-510 ◽

Cited By ~ 37

Author(s):

Debu Tripathy ◽

Peter A. Kaufman ◽

Adam M. Brufsky ◽

Musa Mayer ◽

Marianne Ulcickas Yood ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Treatment Patterns ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Hormone Receptor Positive ◽

First Line Treatment

Download Full-text

Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Metastatic Breast Cancer with Hormone Receptor-positive and HER2-positive (SYSUCC-002)

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-21-3435 ◽

2021 ◽

pp. clincanres.3435.2021

Author(s):

Xin Hua ◽

Xi-wen Bi ◽

Jian-Li Zhao ◽

Yan-Xia Shi ◽

Ying Lin ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Hormone Receptor Positive ◽

First Line Treatment

Download Full-text